Publication:
Cytolytic γδ T-cells and IFNγ-producing CD4-lymphocytes characterise the early response to MTBVAC tuberculosis vaccine.

dc.contributor.authorFelgueres, María-José
dc.contributor.authorEsteso, Gloria
dc.contributor.authorGarcía-Jiménez, Álvaro F
dc.contributor.authorBenguría, Alberto
dc.contributor.authorVázquez, Enrique
dc.contributor.authorAguiló, Nacho
dc.contributor.authorPuentes, Eugenia
dc.contributor.authorDopazo, Ana
dc.contributor.authorMurillo, Ingrid
dc.contributor.authorMartín, Carlos
dc.contributor.authorRodríguez, Esteban
dc.contributor.authorReyburn, Hugh T
dc.contributor.authorValés-Gómez, Mar
dc.contributor.funderFundación La Caixa
dc.contributor.funderMinisterio de Ciencia e Innovación. Centro de Excelencia Severo Ochoa (España)
dc.date.accessioned2025-07-16T13:29:17Z
dc.date.available2025-07-16T13:29:17Z
dc.date.issued2025-03-28
dc.description.abstractInfection with Mycobacterium tuberculosis (Mtb) can produce a wide spectrum of clinical manifestations, ranging from active tuberculosis (TB) to asymptomatic latent infection. Although CD4 T-cells are key immune effectors to control TB, early after infection, the innate immune response must play a role in tackling the disease. Here, we performed in-depth analyses of the acute immune response to MTBVAC, a candidate vaccine engineered from Mtb with the aim of protecting adults from pulmonary TB disease, still a major global challenge. scRNA-seq shows expansion of CD4 and cytotoxic γδ T-cells, data confirmed by flow cytometry. CD4 T-cells exhibited lower HLA-DR and higher L-selectin expression, compared to BCG-stimulation, indicating differential activation or dynamics. Importantly, MTBVAC-activated γδ T-cells had a unique cytotoxic CD16GZMB phenotype, reminiscent of effector cells found in Mtb positive individuals controlling infection. IFN-γ and TNF-α were released in cultures, while IL-17A/F were almost undetectable.
dc.description.peerreviewed
dc.description.tableofcontentsThe group of MVG belongs to the research network Cancer hub-CSIC and to the EU-COST action IMMUNO-model. M.J.F. and A.F.G.J. were registered PhD students at the Molecular Biosciences doctoral program of the Universidad Autónoma de Madrid (UAM).This study was funded by grants RTC-2017-6379-1, PID2021-123795OB-I00 (MVG) and PID2020- 115506RB-I00 (HTR), by MICIU/AEI/ 10.13039/501100011033 and by “ERDF A way of making Europe”; Grant FPU18/01698 (AFGJ) by MICIU/AEI/10.13039/501100011033 and by “ESF Investing in your future” (ESF+); INPhINIT Doctoral Programme from La Caixa Foundation LCF/BQ/DI19/11730039 (MJF); MVG acknowledges financial support from the Spanish State Research Agency, AEI/10.13039/501100011033, through the “Severo Ochoa” Program for Centres of Excellence in R&D [CEX2023-001386-S]. Funders played no role in study design, data collection, analysis and interpretation of data, or the writing of this manuscript.
dc.identifier.citationNPJ Vaccines. 2025 Mar 28;10(1):58.
dc.identifier.journalNPJ Vaccines
dc.identifier.pubmedID40155627
dc.identifier.urihttps://hdl.handle.net/20.500.12105/26829
dc.language.isoeng
dc.publisherNature Publishing Group
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RTC-2017-6379-1
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PID2021-123795OB-I00
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PID2020-115506RB-I00
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/MICIU/AEI/10.13039/501100011033
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/FPU18/01698
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/MICIU/AEI/10.13039/501100011033
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/LCF/BQ/DI19/11730039
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/AEI/10.13039/501100011033
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/CEX2023-001386-S
dc.relation.publisherversionhttps://doi.org/10.1038/s41541-025-01110-3
dc.repisalud.institucionCNIC
dc.repisalud.orgCNICCNIC::Unidades técnicas::Genómica
dc.rights.accessRightsopen access
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.titleCytolytic γδ T-cells and IFNγ-producing CD4-lymphocytes characterise the early response to MTBVAC tuberculosis vaccine.
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Cytolytic γδ T-cells and IFNγ-producing_NPJ Vaccines_2025.pdf
Size:
3.56 MB
Format:
Adobe Portable Document Format